DNLI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DNLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Denali Therapeutics's tax expense for the months ended in Dec. 2023 was $0.0 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.
The historical data trend for Denali Therapeutics's Tax Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Tax Expense | Get a 7-Day Free Trial | -0.35 | 0.82 | -0.58 | 0.02 | 0.03 |
Denali Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Tax Expense | Get a 7-Day Free Trial | -0.01 | - | - | - | 0.03 |
Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.
Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (NAS:DNLI) Tax Expense Explanation
In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.
Thank you for viewing the detailed overview of Denali Therapeutics's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Vicki L Sato | director | 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
Carole Ho | officer: Chief Medical Officer | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Ryan J. Watts | director, officer: President and CEO | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Steve E. Krognes | officer: CFO and Treasurer | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Alexander O. Schuth | officer: COO and Secretary | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Marc Tessier-lavigne | director | 1 DNA WAY, SOUTH SAN FRANCISCO CA 94080 |
Erik Harris | director | 60 LEVERONI COURT, NOVATO CA 94949 |
Douglas K Bratton | 10 percent owner | 201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102 |
Nancy Thornberry | director | SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036 |
David P Schenkein | director | C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Biogen Inc. | 10 percent owner | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Biogen Ma Inc. | 10 percent owner | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Arch Venture Partners Viii, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners Viii, Llc | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Fund Viii, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-15-2022
By sperokesalga sperokesalga • 02-22-2023
By PRNewswire • 11-21-2023
By GuruFocusNews GuruFocusNews • 06-25-2022
By Marketwired • 08-08-2023
By Value_Insider Value_Insider • 10-24-2022
By Marketwired • 08-30-2023
By PRNewswire PRNewswire • 05-16-2023
By GuruFocus Research GuruFocus Editor • 01-06-2023
By Stock market mentor Stock market mentor • 01-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.